Veliparib

Generic Name: Veliparib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Phase 2

Active, not recruiting

Conditions: Anaplastic Astrocytoma
Glioblastoma
Malignant Glioma

Interventions: Radiation: Radiation Therapy
Drug: Temozolomide
Drug: Veliparib

First Posted Date: 2018-07-10

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT03581292

Locations: 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States

and more 160 locations

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Phase 2

Active, not recruiting

Conditions: Essential Thrombocythemia
Atypical Chronic Myeloid Leukemia
Myelodysplastic/Myeloproliferative Neoplasm
Myelofibrosis
Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Polycythemia Vera
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Carboplatin
Drug: Topotecan
Drug: Topotecan Hydrochloride
Drug: Veliparib

First Posted Date: 2017-09-21

Last Posted Date: 2024-07-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT03289910

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 3 locations

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Phase 1

Conditions: Small Cell Lung Cancer SCLC

Interventions: Drug: veliparib
Drug: Topotecan

First Posted Date: 2017-07-24

Last Posted Date: 2021-01-27

Lead Sponsor: Central European Society for Anticancer Drug Research

Target Recruit Count: 30

Registration Number: NCT03227016

Locations: 🇩🇪
Klinik München Gauting, München Gauting, Germany

Expanded Access to Veliparib

Conditions: Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound
Triple Negative Breast Cancer (TNBC)
High Grade Serous Ovarian Cancer
Patients Requiring Veliparib Suspension Formulation

First Posted Date: 2017-04-21

Last Posted Date: 2022-05-24

Lead Sponsor: AbbVie

Registration Number: NCT03123211

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Phase 1

Completed

Conditions: Refractory Mantle Cell Lymphoma
Advanced Solid Neoplasm
Aggressive Non-Hodgkin Lymphoma
Recurrent Solid Neoplasm
T-Cell Non-Hodgkin Lymphoma
Unresectable Solid Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2017-02-23

Last Posted Date: 2024-06-12

Lead Sponsor: Northwestern University

Target Recruit Count: 15

Registration Number: NCT03061188

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Response to PARP Inhibitor Predicted by the RAD51 Assay

Phase 2

Withdrawn

Conditions: Cancer

Interventions: Drug: Veliparib

First Posted Date: 2017-02-07

Last Posted Date: 2024-05-03

Lead Sponsor: University Medical Center Groningen

Registration Number: NCT03044795

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Phase 2

Withdrawn

Conditions: BRCA1 Mutation
Breast Cancer Stage IV
Ovarian Cancer
BRCA2 Mutation

Interventions: Drug: Carboplatin
Drug: Eribulin
Drug: Veliparib

First Posted Date: 2017-01-26

Last Posted Date: 2017-10-10

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Registration Number: NCT03032614

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation
Triple-Negative Breast Cancer

First Posted Date: 2016-12-07

Last Posted Date: 2021-07-21

Lead Sponsor: University of Washington

Registration Number: NCT02985658

Locations: 🇺🇸
Seattle Cancer Care Allliance, Seattle, Washington, United States

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: nivolumab
Drug: paclitaxel
Drug: veliparib
Drug: carboplatin

First Posted Date: 2016-10-25

Last Posted Date: 2019-10-23

Lead Sponsor: AbbVie

Target Recruit Count: 25

Registration Number: NCT02944396

Locations: 🇺🇸
University of Chicago /ID# 153824, Chicago, Illinois, United States
🇺🇸
Duke University Medical Center /ID# 153821, Durham, North Carolina, United States
🇺🇸
University of Alabama at Birmingham - Main /ID# 155135, Birmingham, Alabama, United States

and more 3 locations

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Phase 2

Completed

Conditions: Stage III Rectal Cancer AJCC v7
Rectal Adenocarcinoma
Stage II Rectal Cancer AJCC v7

Interventions: Drug: Capecitabine
Drug: Fluorouracil
Radiation: Intensity-Modulated Radiation Therapy
Drug: Leucovorin
Drug: Oxaliplatin
Biological: Pembrolizumab
Drug: Veliparib

First Posted Date: 2016-10-03

Last Posted Date: 2024-04-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 363

Registration Number: NCT02921256

Locations: 🇺🇸
Island Urology, Honolulu, Hawaii, United States
🇺🇸
Queen's Medical Center, Honolulu, Hawaii, United States
🇺🇸
Straub Clinic and Hospital, Honolulu, Hawaii, United States

and more 645 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy